Gain access now
Download the latest drug budget forecasts and market insights to prepare your 2024 pharmaceutical budget.
Gain actionable insights from our new report.
0.00
%
Projected overall drug price inflation rate for Jan. 1 – Dec. 31, 2024
The expense, interest and expansion of non-acute care continues to increase and expand necessitating an even greater degree of focus by pharmacy leaders on all related dimensions of practice including specialty pharmacy, retail, home infusion and managed care.
Dan Kistner, PharmD
Group Senior Vice President,
Vizient Pharmacy Solutions
-
5
Top spend drugs: adalimumab, immune globulin, ustekinumab, pembrolizumab, denosumab
-
25%
In spaces where there is an originator biologic, biosimilars now make up almost 25% of spend
-
-65%
Percentage decrease of remdesivir in total Vizient pharmacy program participant spend from its peak in the Winter 2022 Outlook
-
301
At time of publication, there were 301 national drug shortages
-
2
Two of the top five agents in the non-acute space are solely specialty infusion
-
51%
Specialty medications accounted for 51% of 2022 drug spend
Want additional resources?
Vizient pharmacy program participants have access to additional resources including price change projections at the individual medication level
Not already enjoying Vizient pharmacy program benefits?
Learn how to access now